Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/81538
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Rehabilitation Sciences | - |
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | SánchezVidanã, DI | - |
dc.creator | Chow, JKW | - |
dc.creator | Hu, SQ | - |
dc.creator | Lau, BWM | - |
dc.creator | Han, YF | - |
dc.date.accessioned | 2019-10-28T05:45:58Z | - |
dc.date.available | 2019-10-28T05:45:58Z | - |
dc.identifier.issn | 1662-4548 | - |
dc.identifier.uri | http://hdl.handle.net/10397/81538 | - |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Research Foundation | en_US |
dc.rights | Copyright © 2019 Sánchez-Vidaña, Chow, Hu, Lau and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | en_US |
dc.rights | The following publication Sánchez-Vidaña DI, Chow JKW, Hu SQ, Lau BWM and Han Y-F (2019) Molecular Targets of Bis (7)-Cognitin and Its Relevance in Neurological Disorders: A Systematic Review. Front. Neurosci. 13:445 is available at https://doi.org/10.3389/fnins.2019.00445 | en_US |
dc.subject | Ache inhibitor | en_US |
dc.subject | Alzheimer's disease | en_US |
dc.subject | B7c | en_US |
dc.subject | Cognitive impairment | en_US |
dc.subject | Nmda antagonist | en_US |
dc.title | Molecular targets of bis (7)-cognitin and its relevance in neurological disorders : a systematic review | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.volume | 13 | - |
dc.identifier.issue | MAY | - |
dc.identifier.doi | 10.3389/fnins.2019.00445 | - |
dcterms.abstract | Background: The exact mechanisms involved in the pathogenesis of neurodegenerative conditions are not fully known. The design of drugs that act on multiple targets represents a promising approach that should be explored for more effective clinical options for neurodegenerative disorders. B7C is s synthetic drug that has been studied for over 20 years and represents a promising multi-target drug for the treatment of neurodegenerative disorders, such as AD. | - |
dcterms.abstract | Aims: The present systematic review, thus, aims at examining existing studies on the effect of B7C on different molecular targets and at discussing the relevance of B7C in neurological disorders. | - |
dcterms.abstract | Methods: A list of predefined search terms was used to retrieve relevant articles from the databases of Embase, Pubmed, Scopus, and Web of Science. The selection of articles was done by two independent authors, who were considering articles concerned primarily with the evaluation of the effect of B7C on neurological disorders. Only full-text articles written in English were included; whereas, systematic reviews, meta-analyses, book chapters, conference subtracts, and computational studies were excluded. | - |
dcterms.abstract | Results: A total of 2,266 articles were retrieved out of which 41 articles were included in the present systematic review. The effect of B7C on molecular targets, including AChE, BChE, BACE-1, NMDA receptor, GABA receptor, NOS, and Kv4.2 potassium channels was evaluated.Moreover, the studies that were included assessed the effect of B7C on biological processes, such as apoptosis, neuritogenesis, and amyloid beta aggregation. The animal studies examined in the review focused on the effect of B7C on cognition and memory. | - |
dcterms.abstract | Conclusions: The beneficial effects observed on different molecular targets and biological processes relevant to neurological conditions confirm that B7C is a promising multi-target drug with the potential to treat neurological disorders. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Frontiers in neuroscience, 2019, v. 13, no. MAY, 445 | - |
dcterms.isPartOf | Frontiers in neuroscience | - |
dcterms.issued | 2019 | - |
dc.identifier.scopus | 2-s2.0-85068548165 | - |
dc.identifier.eissn | 1662-453X | - |
dc.identifier.artn | 445 | - |
dc.description.validate | 201910 bcma | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Sánchez-Vidaña_Molecular_targets_bis(7)-cognitin.pdf | 551.96 kB | Adobe PDF | View/Open |
Page views
127
Last Week
0
0
Last month
Citations as of Apr 14, 2024
Downloads
141
Citations as of Apr 14, 2024
SCOPUSTM
Citations
3
Citations as of Apr 19, 2024
WEB OF SCIENCETM
Citations
4
Citations as of Apr 18, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.